These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 3422560)

  • 1. Facile exchange of the cyano group in highly potent anticancer cyanomorpholinyl anthracyclines.
    Peters JH; Gordon GR; Nolen HW; Tracy M; Thomas DW
    Biochem Pharmacol; 1988 Jan; 37(2):357-61. PubMed ID: 3422560
    [No Abstract]   [Full Text] [Related]  

  • 2. Interactions among membrane transport systems: anthracyclines, calcium antagonists and anti-estrogens.
    Kessel D
    Biochem Pharmacol; 1986 Aug; 35(16):2825-6. PubMed ID: 2943288
    [No Abstract]   [Full Text] [Related]  

  • 3. Biochemical mechanism for resistance to anthracycline antibiotics.
    Inaba M
    Prog Clin Biol Res; 1986; 223():35-44. PubMed ID: 3468518
    [No Abstract]   [Full Text] [Related]  

  • 4. Chemical modification of steffimycin B.
    Wiley PF; Elrod DW; Harper DE
    J Antibiot (Tokyo); 1988 Mar; 41(3):343-51. PubMed ID: 3366692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New potent anthracyclines, barminomycins I and II.
    Uchida T; Imoto M; Takahashi Y; Odagawa A; Sawa T; Tatsuta K; Naganawa H; Hamada M; Takeuchi T; Umezawa H
    J Antibiot (Tokyo); 1988 Mar; 41(3):404-8. PubMed ID: 3163334
    [No Abstract]   [Full Text] [Related]  

  • 6. Sensitivity to anthracyclines in P388/dx leukaemia cells.
    Bossa R; Dasdia T; Galatulas I; Zunino F
    Anticancer Res; 1986; 6(5):1037-9. PubMed ID: 3099628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensely potent morpholinyl anthracyclines.
    Acton EM; Tong GL; Mosher CW; Wolgemuth RL
    J Med Chem; 1984 May; 27(5):638-45. PubMed ID: 6716401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor anthracyclines: recent developments.
    Arcamone F
    Med Res Rev; 1984; 4(2):153-88. PubMed ID: 6374338
    [No Abstract]   [Full Text] [Related]  

  • 9. Membrane transport of anthracyclines.
    Skovsgaard T; Nissen NI
    Pharmacol Ther; 1982; 18(3):293-311. PubMed ID: 6762567
    [No Abstract]   [Full Text] [Related]  

  • 10. Arugomycin, a new anthracycline antibiotic. III. Biological activities of arugomycin and its analogues obtained by chemical degradation and modification.
    Shimosaka A; Kawai H; Hayakawa Y; Komeshima N; Nakagawa M; Seto H; Otake N
    J Antibiot (Tokyo); 1987 Sep; 40(9):1283-91. PubMed ID: 3479414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calmodulin inhibitor trifluoperazine selectively enhances cytotoxic effects of strong vs weak DNA binding antitumor drugs in doxorubicin-resistant P388 mouse leukemia cells.
    Ganapathi R; Grabowski D; Schmidt H; Seshadri R; Israel M
    Biochem Biophys Res Commun; 1985 Sep; 131(2):912-9. PubMed ID: 2932108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Production and biological activity of marcellomycin, an antitumor anthracycline antibiotic, and taxonomy of the producing organism.
    Bush JA; Bradner WT; Tomita K
    J Antibiot (Tokyo); 1982 Sep; 35(9):1174-83. PubMed ID: 6754675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. o-Methylation on anthracyclines and anthracyclinones. New o-methyl ethers of daunorubicin and its analogues.
    Cassinelli G; Di Matteo F; Forenza S; Ripamonti MC; Ruggieri D; Vigevani A; Arcamone F
    Farmaco Sci; 1982 Aug; 37(8):501-13. PubMed ID: 6957317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical assessment of the structure-activity relationship of anthracyclines and related synthetic derivatives.
    Young CW; Raymond V
    Cancer Treat Rep; 1986 Jan; 70(1):51-63. PubMed ID: 2935251
    [No Abstract]   [Full Text] [Related]  

  • 15. New morpholino anthracyclines, MX, MX2, and MY5.
    Umezawa H; Nakajima S; Kawai H; Komeshima N; Yoshimoto H; Urata T; Odagawa A; Otsuki N; Tatsuta K; Otake N
    J Antibiot (Tokyo); 1987 Jul; 40(7):1058-61. PubMed ID: 3476481
    [No Abstract]   [Full Text] [Related]  

  • 16. Single-strand DNA breaks induced by chromophore-modified anthracyclines in P388 leukemia cells.
    Capranico G; Soranzo C; Zunino F
    Cancer Res; 1986 Nov; 46(11):5499-503. PubMed ID: 3463414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mode of action of calcium antagonists which alter anthracycline resistance.
    Kessel D; Wilberding C
    Biochem Pharmacol; 1984 Apr; 33(7):1157-60. PubMed ID: 6585204
    [No Abstract]   [Full Text] [Related]  

  • 18. Chemosensitizers counteracting acquired resistance to anthracyclines and vinca alkaloids in vivo. A new treatment principle.
    Skovsgaard T; Danø K; Nissen NI
    Cancer Treat Rev; 1984 Mar; 11 Suppl A():63-72. PubMed ID: 6375864
    [No Abstract]   [Full Text] [Related]  

  • 19. Cytofluorescence localization of anthracycline antibiotics.
    Egorin MJ; Clawson RE; Cohen JL; Ross LA; Bachur NR
    Cancer Res; 1980 Dec; 40(12):4669-76. PubMed ID: 6934029
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparative redox activities of anthracyclines by microsomes from P388 cells and rat liver.
    Peters JH; Streeter DG; Johl JS; Gordon GR; Tracy M
    Anticancer Res; 1987; 7(6):1189-91. PubMed ID: 3481682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.